1. Home
  2. USA vs DVAX Comparison

USA vs DVAX Comparison

Compare USA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USA

Liberty All-Star Equity Fund

HOLD

Current Price

$6.32

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$15.39

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USA
DVAX
Founded
1986
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.3B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
USA
DVAX
Price
$6.32
$15.39
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$26.50
AVG Volume (30 Days)
880.5K
1.6M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
9.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$330,514,000.00
Revenue This Year
N/A
$24.63
Revenue Next Year
N/A
$15.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
26.73
52 Week Low
$5.62
$9.20
52 Week High
$7.09
$14.63

Technical Indicators

Market Signals
Indicator
USA
DVAX
Relative Strength Index (RSI) 62.73 89.32
Support Level $6.11 $10.78
Resistance Level $6.20 $11.29
Average True Range (ATR) 0.07 0.23
MACD 0.02 0.28
Stochastic Oscillator 100.00 97.94

Price Performance

Historical Comparison
USA
DVAX

About USA Liberty All-Star Equity Fund

Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: